Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TJ011133 |
Synonyms | |
Therapy Description |
TJ011133 (TJC4) is a monocloncal antibody to CD74, which blocks the interaction of CD74 with SIRPA to enhance macrophage mediated phagocytosis of tumor cells (Blood (2019) 134 (Supplement_1): 4063). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TJ011133 | TJC4|TJ 011133|TJ-011133|Lemzoparlimab | CD74 Antibody 3 | TJ011133 (TJC4) is a monocloncal antibody to CD74, which blocks the interaction of CD74 with SIRPA to enhance macrophage mediated phagocytosis of tumor cells (Blood (2019) 134 (Supplement_1): 4063). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04895410 | Phase I | TJ011133 Dexamethasone + TJ011133 Daratumumab + Dexamethasone + TJ011133 Carfilzomib + Dexamethasone + TJ011133 Dexamethasone + Pomalidomide + TJ011133 | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | Terminated | USA | FRA | ESP | DEU | 3 |
NCT03934814 | Phase I | TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Active, not recruiting | USA | 1 |